Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that among postmenopausal women with female pattern hair loss, treatment with topical finasteride 0.5% and minoxidil 2% was more effective at improving hair condition than treatment with topical 17α-estradiol 0.05% and minoxidil 2%, particularly notable at 12-18 months of follow-up.

This study found that a new alcohol-free minoxidil hydrogel formulation showed comparable in vitro efficacy and skin absorption to the commercial minoxidil product for treating androgenetic alopecia.

This study observed no significant improvement of mesotherapy over 5% topical minoxidil for male androgenic alopecia, despite a small increase in hair shaft diameter variation with mesotherapy.

Women pay more for the same 5% minoxidil foam than men, but prices for liquid solutions are similar.

This source provides an overview of expert practices for using topical and low-dose oral minoxidil in treating hair loss, highlighting how dermatologists apply existing literature to ensure safe and effective treatment.

A toddler who accidentally swallowed hair growth medicine experienced serious heart-related side effects but recovered after hospital treatment.

In this study, oral minoxidil (1.25 mg and 2.5 mg) and topical 5% minoxidil significantly promoted hair regrowth in men with androgenetic alopecia over six months, showing comparable efficacy across both oral and topical treatments.

This study found that both oral minoxidil and topical 5% minoxidil were effective and safe for treating female pattern hair loss over 24 weeks, with oral administration not being inferior to topical treatment.

This case report describes severe hypotension, acute coronary syndrome, tachycardia, and acute kidney failure in a man who ingested topical minoxidil, with eventual recovery following intensive treatment.

This case study will explore Minoxidil's effectiveness and cost-efficiency in treating different types of baldness, without providing new clinical findings.

In this randomized clinical trial, researchers reported that both topical and systemic finasteride treatments were similarly effective in increasing hair counts and terminal hair in men with androgenic alopecia after more than 3 months of follow-up.

This study reported no significant improvement in patients with frontal fibrosing alopecia treated with various therapeutic agents, highlighting the need for more evidence-based treatments, especially in those with active disease.

In this study, applying G. glabra root extract to female rats resulted in faster and more extensive hair growth than minoxidil or a control treatment.

This study found that 2 percent topical minoxidil significantly increased nonvellus hair count and showed moderate regrowth compared to placebo in women with mild to moderate androgenetic alopecia, although participants did not notice the difference.

In this study, researchers reported that an herbal extract with dihydroquercetin glucoside, epigallocatechin gallate glucoside, zinc, and glycine showed similar effectiveness and safety to minoxidil in treating androgenetic alopecia over 24 weeks, with no significant differences in hair growth outcomes between the groups.

This study found that treating male pattern androgenetic alopecia with a combination of topical minoxidil and finasteride resulted in better outcomes for hair growth and density compared to using minoxidil alone.

In this study, minoxidil combined with PRP was found to effectively increase hair density in women with female pattern hair loss, but showed no superiority over minoxidil alone. No major side effects were reported.

This review discusses potential causes of androgenic alopecia and explores treatment options, but provides no new clinical results; it emphasizes considering androgen overproduction syndromes in female patients.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

This study found that minoxidil forms a reservoir in the skin, allowing sustained drug delivery even after cleansing, while propylene glycol does not.

This study suggests that scalp rolling could be a promising and affordable adjuvant treatment for alopecia areata, potentially promoting hair regrowth by enhancing the effects of topical medications and inducing collagen.

This study found that topical cyclosporin-A may lead to moderate recovery in patients with severe or refractory alopecia areata, particularly in focal type cases.

This case report describes a 45-year-old man with male pattern baldness who began regrowing hair after receiving fluorouracil treatment for scalp actinic keratosis.

This study reported that the combination of tacrolimus, clobetasol, and minoxidil improved hair measurements and stabilized inflammation in primary cicatricial alopecia patients, with most tolerating the treatment well.

In this self-controlled comparative study of 16 women with Female Pattern Hair Loss, MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced cases compared to standard Minoxidil treatment, though overall effectiveness was similar.

In this study, a combination of 5% minoxidil lotion and 0.25% topical finasteride spray significantly increased hair density and improved photographic assessments in men with androgenetic alopecia compared to the treatments used alone, with all methods showing good tolerability.

Laser treatment followed by a special hair growth solution increased hair count and thickness without side effects.

This case study reports a rare co-occurrence of alopecia areata and vitiligo in a 13-year-old female, suggesting a potential pathogenic link between the two autoimmune skin diseases.